High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia - Trial NCT05768997
Access comprehensive clinical trial information for NCT05768997 through Pure Global AI's free database. This Phase 3 trial is sponsored by Hallym University Medical Center and is currently Recruiting. The study focuses on Anemia. Target enrollment is 312 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hallym University Medical Center
Timeline & Enrollment
Phase 3
Mar 01, 2023
Dec 31, 2025
Primary Outcome
Mean Hb change
Summary
This study is a multicenter, prospective, randomized phase 3 clinical study comparing the
 efficacy and safety of the combination treatment of ESA and high-dose IV iron (darbepoietin
 alfa + ferric derisomaltose/iron isomaltoside) with ESA monotherapy (darbepoietin alfa alone)
 in CIA patients with functional iron deficiency.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05768997
Non-Device Trial